You are here
TIGEN PHARMACEUTICALS
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Long Circulating Liposomal Camptothecins CAP and EAP
Amount: $0.00DESCRIPTION (provided by applicant): Based on the extensive data generated during the phase I portion of our studies, there is sufficient and compelling information to support the fur ...
STTRPhase I2001Department of Health and Human Services National Institutes of Health -
Long Circulating Liposomal Camptothecins CAP and EAP
Amount: $284,000.00DESCRIPTION (provided by applicant): Based on the extensive data generated during the phase I portion of our studies, there is sufficient and compelling information to support the fur ...
STTRPhase II2001Department of Health and Human Services National Institutes of Health -
Potent Topoisomerase I Inhibition For Glioma Therapy
Amount: $133,125.00DESCRIPTION (PROVIDED BY APPLICANT): DB-67 is a promising new silatecan (silylcamptothecin) analog that displays superior blood stability relative to the FDA-approved camptothecin ...
STTRPhase I2001Department of Health and Human Services National Institutes of Health -
N/A
Amount: $100,000.00N/A
STTRPhase I2000Department of Health and Human Services National Institutes of Health -
STABLE CAMPTOTHECIN FORMULATIONS FOR CANCER TREATMENT
Amount: $100,000.00N/A
STTRPhase I1998Department of Health and Human Services
